• On-going

  • Planned

Uliledlimab (CD73 antibody)

More info
  • Indication
  • Phase 1
  • Phase 2
  • Phase 3
  • BLA

NSCLC

1L combo with toripalimab

Ovarian Cancer

2L combo with toripalimab

Solid Tumors

2L combo with atezolizumab

NSCLC

1L combo with chemo and CPI

Givastomig (Claudin 18.2 x 4-1BB bispecific antibody)

More info
  • Indication
  • Phase 1
  • Phase 2
  • Phase 3
  • BLA

GC/GEJ/EAC, PDAC

2L monotherapy

GC/GEJ/EAC

1L combo with chemo and CPI

TJ-L14B (PD-L1 x 4-1BB bispecific antibody)

More info
  • Indication
  • Phase 1
  • Phase 2
  • Phase 3
  • BLA

Solid Tumors

Monotherapy

Eftansomatropin Alfa (long-acting recombinant human growth hormone)

More info
  • Indication
  • Phase 1
  • Phase 2
  • Phase 3
  • BLA

PGHD

Monotherapy

Felzartamab (CD38 antibody)

More info
  • Indication
  • Phase 1
  • Phase 2
  • Phase 3
  • BLA

MM 3L monotherapy

(Registrational trial)

MM

2L TJ202 + Lenalidomide

Lemzoparlimab (CD47 antibody)

More info
  • Indication
  • Phase 1
  • Phase 2
  • Phase 3
  • BLA

MDS

1L combo with azacitidine

Abbreviations

  • 1L = First line
  • 2L = Second line
  • 3L = Third line
  • CPI = Checkpoint inhibitor
  • EAC = Esophageal adenocarcinoma
  • GC = Gastric cancer
  • GEJ =Gastro-esophageal junction adenocarcinoma
  • MDS = Myelodysplastic syndromes
  • MM = Multiple myeloma
  • NSCLC = Non-small cell lung cancer
  • OC = Ovarian cancer
  • PDAC = Pancreatic ductal adenocarcinoma
  • PGHD = Pediatric growth hormone deficiency

Pipeline as of November 2023